
First Patient Dosed with Efti in Phase 3 Trial for Non-Small Cell Lung Cancer
The first patient has been dosed in the phase 3 trial TACTI-004, which will evaluate efti (eftilagimod alfa), a first in class MHC Class 2 agonist, in combination with anti-PD-1 therapy Keytruda (pembrolizumab) and chemotherapy as first-line treatment for …